MARKET

MTCR

MTCR

Metacrine, Inc.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.10
+0.10
+1.11%
Closed 16:00 10/23 EDT
OPEN
9.17
PREV CLOSE
9.00
HIGH
9.19
LOW
8.97
VOLUME
26.84K
TURNOVER
--
52 WEEK HIGH
16.19
52 WEEK LOW
8.90
MARKET CAP
235.89M
P/E (TTM)
-7.0845
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22)
Benzinga · 2d ago
RBC Capital Initiates Coverage On Metacrine with Outperform Rating, Announces Price Target of $25
RBC Capital analyst Brian Abrahams initiates coverage on Metacrine (NASDAQ:MTCR) with a Outperform rating and announces Price Target of $25.
Benzinga · 10/12 09:33
U.S. IPO Week Ahead: Healthcare, Solar Panels, And Chinese Retail In A 9 IPO Week
Five biotechs, two medical device makers, a solar panel mounting manufacturer, and a Chinese retailer are scheduled to raise $2.0 billion in the week ahead.Several companies could join the IPO calendar early in the week, including McAfee and Datto Holding.Street research is expected for 15 companies.The lock-up for Renalytix AI will be expiring on Thursday, 10/15.
Seekingalpha · 10/11 20:55
The Week Ahead In Biotech: J&J Earnings Kickstarts Pharma Earnings, More IPOs In The Pipeline
Biotech stocks advanced along with the broader market in the week ended Oct. 9, although the news flow was quite light.
Benzinga · 10/11 17:29
Metacrine, Prelude Therapeutics See Activist Action
New Enterprise Associates revealed a large investment in biopharmaceutical company Metacrine. Baker Brothers Advisors disclosed an initial position in...
marketwatch.com · 10/03 00:00
The Daily Biotech Pulse: Mesoblast Slumps On FDA Rejection, AstraZeneca's Breakthrough Therapy Designation, 3 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 1)
Benzinga · 10/02 11:35
Metacrine to Present New Data from MET409 Program in NASH at AASLDs The Liver Meeting Digital Experience
New Data Support Robust, Sustained FXR Activation by MET409 in Patients with NASH and Demonstrate Predictability of Liver Fat Reductions as Early as Week 4 of TreatmentSAN DIEGO, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering
GlobeNewswire · 10/01 21:01
Metacrine To Present New Data From MET409 Program In NASH At AASLD's The Liver Meeting Digital Experience
Metacrine to Present New Data from MET409 Program in NASH at AASLD's The Liver Meeting Digital Experience™ SAN DIEGO, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage
Benzinga · 10/01 20:03
More
Forecast
EPSBVPSCFPS
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MTCR. Analyze the recent business situations of Metacrine, Inc. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Institutional Holdings
Institutions: 1
Institutional Holdings: 400
% Owned: 0.00%
Shares Outstanding: 25.92M
TypeInstitutionsShares
Increased
0
0
New
1
400
Decreased
0
0
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.56%
Pharmaceuticals & Medical Research
+0.69%
Key Executives
Chairman/Co-Founder/Director
Richard Heyman
President/Chief Executive Officer/Director
Preston Klassen
Chief Financial Officer/Primary Contact
Trisha Millican
Senior Vice President
Nicholas Smith
Vice President - Operations
Eric Bischoff
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MTCR
Metacrine, Inc. is a United States-based biotechnology company. The Company is engaged in developing therapeutics for metabolic diseases. The Company leverages approximately two mechanistically distinct programs to target type 2 diabetes, NASH and other metabolic diseases and liver disorders. The Company focuses on advancing research in nuclear hormone receptors for treatment of metabolic diseases.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Metacrine Inc stock information, including NASDAQ:MTCR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MTCR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MTCR stock methods without spending real money on the virtual paper trading platform.